Top

Published in:

01-04-2014 | Research

The TPO/c-MPL Pathway in the Bone Marrow may Protect Leukemia Cells from Chemotherapy in AML Patients

Authors: Zeng Dong-Feng, Liu Ting, Zhang Yong, Chang Cheng, Zhang Xi, Kong Pei-Yan

Published in: Pathology & Oncology Research | Issue 2/2014

Abstract

Accumulating evidence indicates that the interaction of human LSCs (leukemic stem cells) with the hematopoietic microenvironment, mediated by the thrombopoietin (TPO)/c-MPL pathway, may be an underlying mechanism for resistance to cell cycle–dependent cytotoxic chemotherapy. However, the role of TPO/c-MPL signaling in AML (acute myelogenous leukemia) chemotherapy resistance hasn’t been fully understood. The c-MPL and TPO levels in different AML samples were measured by flow cytometry and ELISA. We also assessed the TPO levels in the osteoblasts derived from bone mesenchymal stem cells (BMSCs). The survival rate of an AML cell line that had been co-cultured with different BMSC-derived osteoblasts was measured to determine the IC₅₀ of an AML chemotherapy drug daunorubicin (DNR). The levels of TPO/c-MPL in the initial and relapse AML patients were significantly higher than that in the control (P < 0.05). The osteoblasts derived from AML patients’ BMSCs secreted more TPO than the osteoblasts derived from normal control BMSCs (P < 0.05). A strong positive correlation between the TPO level and c-MPL expression was found in the bone marrow mononuclear cells of the relapse AML patients. More importantly, the IC₅₀ of DNR in the HEL + AML-derived osteoblasts was the highest among all co-culture systems. High level of TPO/c-MPL signaling may protect LSCs from chemotherapy in AML. The effects of inhibition of the TPO/c-MPL pathway on enhancing the chemotherapy sensitivity of AML cells, and on their downstream effector molecules that direct the interactions between patient-derived blasts and leukemia repopulating cells need to be further studied.

She M, Niu X, Chen X, Li J, Zhou M, He Y, Le Y, Guo K (2012) Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. Cancer Lett 318(2):173–179. doi:10.1016/j.canlet.2011.12.017 PubMedCrossRef

Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF (2009) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113(24):6206–6214. doi:10.1182/blood-2008-06-162123 PubMedCentralPubMedCrossRef

Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, Uchida N, Suzuki N, Sone A, Najima Y, Ozawa H, Wake A, Taniguchi S, Shultz LD, Ohara O, Ishikawa F (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2(17):17ra19. doi:10.1126/scitranslmed.3000349 CrossRef

Lane SW, Scadden DT, Gilliland DG (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114(6):1150–1157. doi:10.1182/blood-2009-01-202606 PubMedCentralPubMedCrossRef

Blanco TM, Mantalaris A, Bismarck A, Panoskaltsis N (2010) The development of a three-dimensional scaffold for ex vivo biomimicry of human acute myeloid leukaemia. Biomaterials 31(8):2243–2251. doi:10.1016/j.biomaterials.2009.11.094 PubMedCrossRef

Ishikawa FYS, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, Ohara O, Akashi K, Harada M, Shultz LD (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25:1315–1321PubMedCrossRef

Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113(24):6215–6224. doi:10.1182/blood-2008-05-158311 PubMedCentralPubMedCrossRef

Jawad MSC, Mony U, Grundy M, Russell NH, Pallis M (2010) Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 24:74–80PubMedCrossRef

Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Dohner K, Peschel C, Oostendorp RA, Gotze KS (2011) Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. Cancer Res 71(13):4696–4706. doi:10.1158/0008-5472.CAN-10-4136 PubMedCrossRef

10.

Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA (2011) Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 118(10):2849–2856. doi:10.1182/blood-2011-03-345165 PubMedCentralPubMedCrossRef

11.

Guo YBS, Luo M (1999) Study of thrombopoietin and its recptor in the acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi 20:120–123PubMed

12.

Schroder JK, Kolkenbrock S, Tins J, Kasimir-Bauer S, Seeber S, Schutte J (2000) Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia. Leuk Res 24(5):401–409PubMedCrossRef

13.

Li L, Xie T (2005) Stem cell niche: structure and function. Annu Rev Cell Dev Biol 21:605–631. doi:10.1146/annurev.cellbio.21.012704.131525 PubMedCrossRef

14.

Adams GB, Scadden DT (2006) The hematopoietic stem cell in its place. Nat Immunol 7(4):333–337PubMedCrossRef

15.

LE Wilson A, Trumpp A (2009) Balancing dormant and self-renewing hematopoietic stem cells. Curr Opin Genet Dev 19:461–468PubMedCrossRef

16.

Yoshihara HAF, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, Gomei Y, Iwasaki H, Matsuoka S, Miyamoto K, Miyazaki H, Takahashi T, Suda T (2007) Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1:685–697PubMedCrossRef

17.

Matsumura IKY, Kato T, Ikeda H, Ishikawa J, Horikawa Y, Hashimoto K, Moriyama Y, Tsujimura T, Nishiura T (2005) Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood 86:703–709

18.

Corazza FHC, D’Hondt S, Ferster A, Kentos A, Benoît Y, Sariban E (2006) Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia. Blood 107:2525–2530PubMedCrossRef

19.

Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339–3347PubMedCentralPubMedCrossRef

20.

Sitnicka E, Lin N, Priestley GV, Fox N, Broudy VC, Wolf NS, Kaushansky K (1996) The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 87(12):4998–5005PubMed

21.

Ku H, Yonemura Y, Kaushansky K, Ogawa M (1996) Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 87(11):4544–4551PubMed

22.

Fox N, Priestley G, Papayannopoulou T, Kaushansky K (2002) Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest 110(3):389–394. doi:10.1172/JCI15430 PubMedCentralPubMedCrossRef

23.

Wu YX, Wang HY, Wang W (2010) Measurement and clinical significance of serum TPO and LDH levels in patients with myelodysplastic syndrome and acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 18(3):671–674PubMed

24.

Wetzler MBM, Bernstein SH, Blumenson L, Stewart C, Barcos M, Mrózek K, Block AW, Herzig GP, Bloomfield CD (1997) Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensie chemotherapy. Clin Oncol 15:2262–2268

25.

Arai F, Yoshihara H, Hosokawa K, Nakamura Y, Gomei Y, Iwasaki H, Suda T (2009) Niche regulation of hematopoietic stem cells in the endosteum. Ann N Y Acad Sci 1176:36–46. doi:10.1111/j.1749-6632.2009.04561.x PubMedCrossRef

Title: The TPO/c-MPL Pathway in the Bone Marrow may Protect Leukemia Cells from Chemotherapy in AML Patients
Authors: Zeng Dong-Feng
Liu Ting
Zhang Yong
Chang Cheng
Zhang Xi
Kong Pei-Yan
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-013-9696-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

MicroRNA-21 Promotes Oral Cancer Invasion via the Wnt/β-Catenin Pathway by Targeting DKK2

Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas

MicroRNA-181a Functions as an Oncomir in Gastric Cancer by Targeting the Tumour Suppressor Gene ATM

Tumor Growth Attenuating Effects of Naringenin

Evaluation of the Accuracy of Preoperative MRI in Measuring Myometrial Infiltration in Endometrial Carcinoma

Expression of Cell Cycle-Related Proteins, p16, p53 and p63 as Important Prognostic Markers in Gallbladder Adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer